Abstract PO2-18-01: Assessment of Initial Dosing and Dose Management of Sacituzumab Govitecan-hziy (SG) and How Dosing Practices Impact Duration of Therapy (DOT)
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs23-po2-18-01
Abstract: Background: As the Phase 3 ASCENT trial’s safety analysis found that a 10m/kg dose of SG resulted in better efficacy than treatment with a lower dose, this examination sought to use real-world data to evaluate… read more here.
Keywords: cancer; starting dose; dot pts; dose reductions ... See more keywords